Sugi Predict

Sugi Predict / Compounds / SCHEMBL14719219

SCHEMBL14719219

SCHEMBL14719219

C=CS(=O)(=O)Nc1cccc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 6/20 0.47
▸ CA2 P00918 6/20 0.47
▸ CA9 Q16790 6/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA3 P07451 1/20 0.47
▸ CA4 P22748 1/20 0.47
▸ CA6 P23280 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ CA5B Q9Y2D0 1/20 0.47
▸ TGM2 P21980 1/20 0.43
▸ LPL P06858 2/20 0.41
▸ LIPG Q9Y5X9 2/20 0.41
▸ GSTO1 P78417 1/20 0.39
▸ EGFR P00533 3/20 0.39
▸ SRC P12931 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.38
▸ BTK Q06187 2/20 0.38
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31438926 0.84 CA1 (0.50) CA1CA2CA9CA12CA3
SCHEMBL393567 0.84 CA1 (0.50) CA1CA2CA9CA12CA3
SCHEMBL19279312 0.84 CA1 (0.45) CA1CA2CA9CA12CA3
SCHEMBL10214999 0.82 CA1 (0.68) CA1CA2CA9CA12CA3
SCHEMBL16238072 0.82 LPL (0.48) CA1CA2CA9CA12CA3
SCHEMBL10391 0.81 HTT (0.49) CA1CA2CA9CA12CA3
SCHEMBL17160118 0.80 CA2 (0.49) CA1CA2CA9CA12CA3
SCHEMBL11894843 0.80 HTR6 (0.51) CA1CA2CA9CA12CA3
SCHEMBL2508131 0.78 LPL (0.48) CA1CA2CA9CA12CA3
SCHEMBL1075440 0.78 OPRM1 (0.46) CA1CA2CA9CA12CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-06-22 — — US disclosed
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-06-22 — — US disclosed
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-06-22 — — US disclosed
US-11623921-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-04-11 — — US disclosed
CN-110511209-B Indole carboxamide compounds useful as kinase inhibitors 百时美施贵宝公司 2022-07-05 — — CN disclosed
US-11053197-B2 Carbazole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-06 — — US disclosed
US-11053197-B2 Carbazole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-06 — — US disclosed
US-20210107891-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-04-15 — — US disclosed
US-20210107891-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-04-15 — — US disclosed
CN-107108583-B Indole carboxamide compounds useful as kinase inhibitors 百时美施贵宝公司 2020-11-13 — — CN disclosed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 — — US disclosed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 — — US disclosed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 — — US disclosed
US-9115141-B2 Substituted isoquinolinones and methods of treatment thereof INFINITY PHARMACEUTICALS, INC. (US) 2015-08-25 — — US disclosed
US-20140288048-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. 2014-09-25 — — US disclosed
US-8785470-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2014-07-22 — — US disclosed
EP-2751093-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Infinity Pharmaceuticals, Inc. (US) 2014-07-09 — — EP disclosed
US-20140100214-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2014-04-10 — — US disclosed
WO-2013032591-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS INC. (US) 2013-03-07 — — WO disclosed
US-20130053362-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLKINE, LLC (US) 2013-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288048-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AKT3, PIK3CA, AKT1 CA1 2993/4885CA2 2421/4885CA9 2480/4885
US-20130053362-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AKT3, PIK3CA, AKT1 CA1 2993/4885CA2 2421/4885CA9 2480/4885
US-20140100214-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AKT3, PIK3CA, AKT1 CA1 2993/4885CA2 2421/4885CA9 2480/4885
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 CA1 1518/4885CA2 615/4885CA9 1536/4885
US-11623921-B2 Indole carboxamide compounds BTK, JAK2, BRD4 CA1 1518/4885CA2 615/4885CA9 1536/4885
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 CA1 1518/4885CA2 615/4885CA9 1536/4885
US-20210107891-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 CA1 1518/4885CA2 615/4885CA9 1536/4885
US-11053197-B2 Carbazole derivatives BTK, SYK, JAK2 CA1 3569/4885CA2 1487/4885CA9 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.